AGILON HEALTH INC (AGL)
US00857U1079 - Common Stock
Overall AGL gets a fundamental rating of 3 out of 10. We evaluated AGL against 117 industry peers in the Health Care Providers & Services industry. AGL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. AGL shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
In the past year AGL has reported negative net income.
In the past year AGL has reported a negative cash flow from operations.
In the past 5 years AGL always reported negative net income.
AGL had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
AGL has a worse Return On Assets (-15.08%) than 74.14% of its industry peers.
AGL has a worse Return On Equity (-39.67%) than 62.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.08% | ||
| ROE | -39.67% | ||
| ROIC | N/A |
ROA(3y)-15.66%
ROA(5y)-26.12%
ROE(3y)-29.05%
ROE(5y)-181.24%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AGL has a worse Gross Margin (7.13%) than 81.03% of its industry peers.
In the last couple of years the Gross Margin of AGL has declined.
AGL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 7.13% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-23.83%
GM growth 5YN/A
2. Health
2.1 Basic Checks
AGL does not have a ROIC to compare to the WACC, probably because it is not profitable.
AGL has less shares outstanding than it did 1 year ago.
The debt/assets ratio for AGL has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.46 indicates that AGL is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of AGL (2.46) is better than 65.52% of its industry peers.
AGL has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
AGL has a better Debt to Equity ratio (0.05) than 81.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.46 |
ROIC/WACCN/A
WACC9.35%
2.3 Liquidity
AGL has a Current Ratio of 1.51. This is a normal value and indicates that AGL is financially healthy and should not expect problems in meeting its short term obligations.
AGL has a better Current ratio (1.51) than 60.34% of its industry peers.
AGL has a Quick Ratio of 1.51. This is a normal value and indicates that AGL is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of AGL (1.51) is better than 66.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.51 | ||
| Quick Ratio | 1.51 |
3. Growth
3.1 Past
AGL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -88.46%.
Looking at the last year, AGL shows a very strong growth in Revenue. The Revenue has grown by 59.38%.
Measured over the past years, AGL shows a very strong growth in Revenue. The Revenue has been growing by 52.45% on average per year.
EPS 1Y (TTM)-88.46%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-192.86%
Revenue 1Y (TTM)59.38%
Revenue growth 3Y52.45%
Revenue growth 5YN/A
Revenue growth Q2Q18.22%
3.2 Future
The Earnings Per Share is expected to grow by 48.20% on average over the next years. This is a very strong growth
AGL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 25.53% yearly.
EPS Next Y37.99%
EPS Next 2Y27.26%
EPS Next 3Y27.28%
EPS Next 5Y48.2%
Revenue Next Year42.41%
Revenue Next 2Y33.38%
Revenue Next 3Y29.43%
Revenue Next 5Y25.53%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for AGL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AGL. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
AGL's earnings are expected to grow with 27.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.26%
EPS Next 3Y27.28%
5. Dividend
5.1 Amount
AGL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AGILON HEALTH INC
NYSE:AGL (4/26/2024, 7:04:00 PM)
After market: 5 0 (0%)5
-0.13 (-2.53%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.05B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.08% | ||
| ROE | -39.67% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 7.13% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover2.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.51 | ||
| Quick Ratio | 1.51 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-88.46%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y37.99%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)59.38%
Revenue growth 3Y52.45%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y